Royalty Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Royalty Pharma Plc
RPRX Stock  USD 26.43  0.03  0.11%   
Royalty Pharma financial statements provide useful quarterly and yearly information to potential Royalty Pharma Plc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Royalty Pharma financial statements helps investors assess Royalty Pharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Royalty Pharma's valuation are summarized below:
Gross Profit
1.3 B
Profit Margin
0.5053
Market Capitalization
15.6 B
Enterprise Value Revenue
7.7608
Revenue
2.3 B
We have found one hundred twenty available trending fundamental ratios for Royalty Pharma Plc, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Royalty Pharma Plc recent market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Enterprise Value is likely to drop to about 17 B in 2024

Royalty Pharma Total Revenue

2.47 Billion

Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 196.5 M, Total Revenue of 2.5 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 5.07, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Royalty Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets17.2 B16.4 B8.3 B
Slightly volatile
Other Current Liabilities153.5 M146.2 M101.9 M
Slightly volatile
Total Current Liabilities132.4 M161.4 M230.4 M
Slightly volatile
Total Stockholder Equity6.9 B6.5 B3.3 B
Slightly volatile
Other Liabilities2.4 M2.2 M2.6 M
Slightly volatile
Accounts Payable15.9 M15.2 M6.1 M
Slightly volatile
Cash343.9 M477 M626.5 M
Slightly volatile
Other Assets16.3 B15.5 B9.5 B
Slightly volatile
Common Stock Shares Outstanding409.1 M602.9 M386.2 M
Slightly volatile
Short Term Investments17.4 M18.3 M481.8 M
Pretty Stable
Inventory1.091.1598.2 M
Pretty Stable
Other Current Assets5.8 M3.8 M8.4 M
Slightly volatile
Total Liabilities6.6 B6.3 B3.6 B
Slightly volatile
Common Stock42.8 K45 K656.5 M
Pretty Stable
Property Plant Equipment2.6 K2.7 K51 K
Slightly volatile
Intangible Assets1.7 M1.8 M32.6 M
Very volatile
Net Tangible Assets3.7 B6.5 B2.8 B
Slightly volatile
Total Current Assets1.6 B1.3 B1.2 B
Slightly volatile
Short and Long Term Debt Total8.5 B6.1 B7.1 B
Slightly volatile
Net Debt5.9 B5.7 B5 B
Slightly volatile
Non Current Assets Total14.2 B15.1 B10.8 B
Slightly volatile
Non Currrent Assets Other14.8 B14.1 B1.9 B
Slightly volatile
Long Term Debt6.8 B6.1 B6.3 B
Pretty Stable
Cash And Short Term Investments470.5 M495.3 M2 B
Slightly volatile
Net Receivables813.8 M775.1 M283.4 M
Slightly volatile
Common Stock Total Equity91.5 K96.3 K2.2 B
Slightly volatile
Long Term Debt Total6.9 B7 B6.3 B
Slightly volatile
Liabilities And Stockholders Equity17.5 B16.4 B13.6 B
Slightly volatile
Non Current Liabilities Total6.9 B6.1 B6.3 B
Pretty Stable
Net Invested Capital13.2 B12.7 B11.6 B
Slightly volatile
Long Term Investments14.1 B15.1 B10.7 B
Slightly volatile
Short and Long Term Debt1.2 B1.1 B543.9 M
Slightly volatile
Capital Stock102.6 K108 K2.2 B
Slightly volatile
Net Working Capital1.3 B1.1 B1.8 B
Slightly volatile
Short Term Debt1.9 B1.1 B937 M
Slightly volatile
Current Deferred Revenue24.8 M27.9 M30.4 M
Slightly volatile
Noncontrolling Interest In Consolidated Entity3.6 B3.5 B4.8 B
Slightly volatile
Retained Earnings Total Equity2.3 B2.3 B2 B
Slightly volatile
Capital Surpluse3.7 B4.2 B3.1 B
Slightly volatile
Non Current Liabilities Other1.4 M900 K2.3 M
Slightly volatile

Royalty Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Research Development57.5 M52 M81.3 M
Slightly volatile
Selling General Administrative262.2 M249.7 M101.8 M
Slightly volatile
Interest Income45 M72.3 M25.2 M
Slightly volatile
Depreciation And Amortization414.9 M395.1 M78.4 M
Slightly volatile
Other Operating Expenses858 M862.4 M728.4 M
Slightly volatile
EBITDA1.8 B1.9 B1.4 B
Slightly volatile
Non Recurring1.2 B1.4 B1.5 B
Slightly volatile

Royalty Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation17.9 M20.5 M12.1 M
Slightly volatile
End Period Cash Flow453.2 M477 M1.4 B
Slightly volatile
Begin Period Cash Flow1.1 B1.7 B1.5 B
Slightly volatile
Dividends Paid418.6 M358.3 M615.2 M
Slightly volatile
Stock Based Compensation2.5 M2.4 M4.6 M
Slightly volatile
Cash And Cash Equivalents Changes145.1 M152.7 M625.8 M
Slightly volatile
Cash Flows Other Operating2.2 B2.4 B2 B
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.075.339911.621
Slightly volatile
Dividend Yield0.03610.02850.0395
Slightly volatile
PTB Ratio3.831.92654.269
Slightly volatile
Days Sales Outstanding126120126
Slightly volatile
Book Value Per Share14.7822.529614.6451
Slightly volatile
Operating Cash Flow Per Share4.06.67514.4677
Slightly volatile
Stock Based Compensation To Revenue0.00150.0010.0022
Slightly volatile
Capex To Depreciation340324117
Slightly volatile
PB Ratio3.831.92654.269
Slightly volatile
EV To Sales13.577.74314.6204
Slightly volatile
ROIC0.120.11780.0695
Pretty Stable
Inventory Turnover0.150.13414.3054
Slightly volatile
Net Income Per Share2.532.53541.8694
Slightly volatile
Days Of Inventory On Hand1.0E-41.0E-4394
Pretty Stable
Payables Turnover31.4536.970429.7281
Pretty Stable
Sales General And Administrative To Revenue0.06070.10610.0706
Slightly volatile
Average Inventory0.550.57262.9 M
Slightly volatile
Research And Ddevelopement To Revenue0.0210.02210.0644
Very volatile
Capex To Revenue0.831.051.093
Slightly volatile
Cash Per Share1.051.10663.4891
Pretty Stable
POCF Ratio4.04.20819.4742
Slightly volatile
Interest Coverage5.067.97145.3136
Slightly volatile
Payout Ratio0.30.31581.0376
Pretty Stable
Capex To Operating Cash Flow0.891.091.2088
Slightly volatile
Days Payables Outstanding9.389.872851.6136
Slightly volatile
Income Quality2.012.63281.7983
Slightly volatile
ROE0.190.17390.156
Very volatile
EV To Operating Cash Flow5.86.101912.6952
Slightly volatile
PE Ratio10.5311.079357.0714
Pretty Stable
Return On Tangible Assets0.09110.06930.1059
Slightly volatile
Earnings Yield0.09480.09030.0468
Slightly volatile
Intangibles To Total Assets1.0E-41.0E-40.2588
Slightly volatile
Net Debt To EBITDA4.332.99814.305
Slightly volatile
Current Ratio8.577.89588.4732
Pretty Stable
Receivables Turnover3.533.03782.969
Slightly volatile
Graham Number19.5528.840720.2606
Slightly volatile
Shareholders Equity Per Share11.0914.581111.6207
Slightly volatile
Debt To Equity1.30.94011.2219
Slightly volatile
Capex Per Share4.115.365.146
Slightly volatile
Revenue Per Share3.725.26043.9482
Slightly volatile
Interest Debt Per Share12.5814.125213.6802
Slightly volatile
Debt To Assets0.520.37450.5037
Slightly volatile
Enterprise Value Over EBITDA9.189.660224.2724
Slightly volatile
Short Term Coverage Ratios2.352.474.2213
Slightly volatile
Price Earnings Ratio10.5311.079357.0714
Pretty Stable
Operating Cycle114120338
Pretty Stable
Price Book Value Ratio3.831.92654.269
Slightly volatile
Days Of Payables Outstanding9.389.872851.6136
Slightly volatile
Dividend Payout Ratio0.30.31581.0376
Pretty Stable
Price To Operating Cash Flows Ratio4.04.20819.4742
Slightly volatile
Pretax Profit Margin0.750.7220.6082
Slightly volatile
Ebt Per Ebit1.081.13940.977
Very volatile
Operating Profit Margin0.540.63370.6034
Slightly volatile
Effective Tax Rate0.770.730.4062
Slightly volatile
Company Equity Multiplier1.992.51012.4005
Pretty Stable
Long Term Debt To Capitalization0.570.48460.5368
Slightly volatile
Total Debt To Capitalization0.580.48460.5457
Slightly volatile
Return On Capital Employed0.110.0920.0918
Pretty Stable
Debt Equity Ratio1.30.94011.2219
Slightly volatile
Ebit Per Revenue0.540.63370.6034
Slightly volatile
Quick Ratio8.317.89588.3113
Pretty Stable
Dividend Paid And Capex Coverage Ratio8.768.33822.1178
Slightly volatile
Net Income Per E B T0.70.66750.6889
Slightly volatile
Cash Ratio4.352.95594.4861
Slightly volatile
Operating Cash Flow Sales Ratio0.781.26890.9179
Slightly volatile
Days Of Inventory Outstanding1.0E-41.0E-4394
Pretty Stable
Days Of Sales Outstanding126120126
Slightly volatile
Cash Flow Coverage Ratios0.250.4870.2571
Slightly volatile
Price To Book Ratio3.831.92654.269
Slightly volatile
Capital Expenditure Coverage Ratio0.90.95258
Pretty Stable
Price Cash Flow Ratio4.04.20819.4742
Slightly volatile
Enterprise Value Multiple9.189.660224.2724
Slightly volatile
Debt Ratio0.520.37450.5037
Slightly volatile
Cash Flow To Debt Ratio0.250.4870.2571
Slightly volatile
Price Sales Ratio5.075.339911.621
Slightly volatile
Return On Assets0.0790.06930.0663
Very volatile
Asset Turnover0.150.14370.1465
Slightly volatile
Net Profit Margin0.540.4820.4477
Very volatile
Gross Profit Margin0.690.76190.9062
Slightly volatile
Price Fair Value3.831.92654.269
Slightly volatile
Return On Equity0.190.17390.156
Very volatile

Royalty Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap12.7 B14.7 B15.6 B
Slightly volatile
Enterprise Value17 B20 B21.1 B
Pretty Stable

Royalty Fundamental Market Drivers

Forward Price Earnings8.547
Cash And Short Term Investments495.3 M

Royalty Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue27.9 M24.8 M
Total Revenue2.4 B2.5 B
Cost Of Revenue560.7 M588.7 M
Sales General And Administrative To Revenue 0.11  0.06 
Research And Ddevelopement To Revenue 0.02  0.02 
Capex To Revenue 1.05  0.83 
Revenue Per Share 5.26  3.72 
Ebit Per Revenue 0.63  0.54 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY